GE HealthCare Technologies has climbed back in recent weeks after a weak run earlier in the year, which puts fresh focus on whether its current share price lines up with the earnings power backing it. With the stock closing at US$69.57, the key issue for you is how much of the business’s profit story is already reflected in that tag.
-
The share price is still down 16.0% year to date, which makes the recent rebound an open question about whether the market is reassessing the earnings outlook or just catching up from earlier pessimism.
-
The planned US$945 million Sofie Biosciences acquisition may support future earnings by expanding radiopharmaceutical capabilities, but it also concentrates more capital and execution risk into businesses closely tied to Pharmaceutical Diagnostics and molecular imaging.
-
There is a second opinion on GE HealthCare Technologies worth weighing. See what analysts think GE HealthCare Technologies’s shares could be worth.
For investors, the debate is whether GE HealthCare’s current valuation is adequately supported by its earnings profile given the share price reset and the mix of growth investments and ongoing legal and management challenges.
If you are weighing GE HealthCare Technologies against other earnings driven opportunities, comparing it with 33 high quality undervalued stocks can help you see how its pricing stacks up against companies with similar quality signals.
Does GE HealthCare Technologies Look Undervalued on Earnings?
The P/E ratio suits GE HealthCare Technologies because earnings still sit at the center of how investors frame this business. On that score, the stock trades on a P/E of 15.8x, which is well below the Medical Equipment sector average of 25.3x and also under the broader peer group on about 30.1x. For a reader, that gap means the market is currently paying less for each dollar of GE HealthCare earnings than for many similar healthcare equipment players.
Because the recent Sofie Biosciences deal channels more capital into radiopharmaceuticals, the current multiple matters as a check on how much optimism is already in the price. The tailored fair multiple that factors in GE HealthCare’s own growth profile, profitability, size and risk sits above the present 15.8x P/E, which indicates that the stock screens as undervalued on this framework. Despite the legal investigation and CFO change raising headline risk, the market multiple still prices GE HealthCare at a discount to both the sector and that company specific fair yardstick. Explore the numbers behind GE HealthCare Technologies’s P/E valuation.
